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Abstract Beta-amyloid (Ab) is thought to be a key con-
tributortothepathogenesisofAlzheimerdisease(AD)inthe
general population and in adults with Down syndrome (DS).
Different assembly states of Ab have been identiﬁed that
may be neurotoxic. Ab oligomers can assemble into soluble
preﬁbrillar oligomers, soluble ﬁbrillar oligomers and insol-
uble ﬁbrils. Using a novel antibody, OC, recognizing ﬁbrils
and soluble ﬁbrillar oligomers, we characterized ﬁbrillar Ab
deposits in AD and DS cases. We further compared human
specimens to those obtained from the Tg2576 mouse model
of AD. Our results show that accumulation of ﬁbrillar
immunoreactivityissigniﬁcantlyincreasedinADrelativeto
nondemented aged subjects and those with select cognitive
impairments (p\0.0001). Further, there was a signiﬁcant
correlation between the extent of frontal cortex ﬁbrillar
deposit accumulation and dementia severity (MMSE r =
-0.72). In DS, we observe an early age of onset and age-
dependent accumulation of ﬁbrillar OC immunoreactivity
with little pathology in similarly aged non-DS individuals.
Tg2576 mice show ﬁbrillar accumulation that can be
detected as young as 6 months. Interestingly, ﬁbril-speciﬁc
immunoreactivity was observed in diffuse, thioﬂavine
S-negative Ab deposits in addition to more mature neuritic
plaques. These results suggest that ﬁbrillar deposits are
associatedwithdiseaseinbothADandinadultswithDSand
their distribution within early Ab pathology associated with
diffuse plaques and correlation with MMSE suggest that
these deposits may not be as benign as previously thought.
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Introduction
Alzheimer disease (AD) is associated with the progressive
development of cognitive dysfunction and neuropatho-
logical accumulation of neuroﬁbrillary tangles and senile
plaques (SP) [37, 53, 55, 67]. A major constituent of SP is
b-amyloid (Ab), which is a 39–42 amino acid peptide
cleaved from a longer amyloid precursor protein (APP)
[25, 33]. Ab can adopt a misfolded structure including
preﬁbrillar oligomeric and ﬁbrillar assembly states [9, 24,
28, 42, 70]. Some assembly states of Ab may be more toxic
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DOI 10.1007/s00401-009-0530-3than others [18, 42, 44, 71]. For example, Ab oligomers are
toxic to neurons both in vitro [18, 42] and in vivo [44, 71].
Thus, measuring the extent of different and speciﬁc
assembly states of Ab may identify species that are more
strongly linked to cognition in AD and can serve as a
biomarker and possible therapeutic target [36].
Individuals with Down syndrome (DS) also develop AD
pathology but in a progressive age-dependent manner [30,
49, 50, 77] and as such, are at high risk for the development
of dementia [41, 46]. Clinical signs of dementia are more
commonly observed when individuals are over 50 years of
age [8, 41, 63, 69]. By 40 years of age, however, all
individuals with DS have neuropathological changes
including senile plaques and neuroﬁbrillary tangles con-
sistent with AD [50, 76, 77]. By studying individuals with
varying ages at death, the progressive accumulation of Ab
ﬁbrils can be established as occurring early or late in AD
pathogenesis.
We hypothesized that one conformation of Ab that may
be linked to cognition in human brain is the accumulation
of soluble and insoluble ﬁbrils. We previously described a
novel antibody, OC, that selectively recognized ﬁbrils and
ﬁbrillar oligomers [35] that are distinct from preﬁbrillar
oligomer assembly states. This new reagent was used to
characterize and quantify the extent of ﬁbrillar deposit
accumulation in human brain by immunohistochemistry as
a function of age (in DS) and dementia status (in AD). We
further conﬁrmed the age and disease-speciﬁc changes in
Ab ﬁbrils by examining Tg2576 (overexpressing human
APP with the Swedish mutation [31]) mice with a wide
range of ages and quantifying ﬁbril accumulation.
Methods
Human autopsy cases
The ﬁrst group of seven autopsy cases was used to char-
acterize OC-associated pathology (neuroﬁbrillary tangles,
dystrophic neurites and glial activation). This study inclu-
ded two control cases (95 and 69 years) and ﬁve AD cases
(65–89 years). A second group of 14 autopsy cases with
MMSE scores ranging between 0 and 30 was used for OC
load analyses and to measure associations between cogni-
tion and neuropathology (Table 1). Finally, tissues from a
group of individuals with DS and similarly aged controls
were compared (Table 1). Braak and Braak neuroﬁbrillary
tangle and senile plaque staging was provided as part of the
standard neuropathology process [5–7]. A ﬁnal neuropa-
thology diagnosis was made according to NIA/Reagan
criteria [67].
Brain tissue samples were obtained from the University
of California Alzheimer Disease Research Center (UCI-
ADRC) and from the NICHD Brain and Tissue Bank for
Developmental Disorders (under contracts N01-4-3368 and
N01-HD-4-3383). The hippocampus and midfrontal gyrus
was dissected from 4% paraformaldehyde-ﬁxed coronal
slices and sectioned at 50 lm using a vibratome. Free-
ﬂoating sections were stored in PBS with 0.02% sodium
azide prior to use in immunohistochemical or histology
experiments.
Transgenic mouse tissue
Fixed free-ﬂoating 4% paraformaldehyde-ﬁxed sections
that included the hippocampus from Tg2576 animals at 3,
6, 9, 12, 18 and 24 months (n = 5/group) were compared
with aged wild type animals that were either 18 months
(n = 5) or 24 months (n = 5) of age. Brain tissues were
obtained from the UCI-ADRC.
Immunohistochemistry
For single-labeling experiments, all sections were washed
with 0.1 M Tris-buffered saline (TBS), pH 7.5, and then
pretreated with 3% hydrogen peroxide in 10% methanol
to block endogenous peroxidase activity. Sections were
subsequently washed in TBS with 0.1% Triton X-100
Table 1 Case demographics
Group N Age (years) Sex PMI (h) MMSE Interval (Mos) Braak stage
Study 1
Nondemented 4 80.0 (7.12) 4F/0 M 3.6 (1.26) 29.5(0.58) 6.9 (4.2) 3 (II), 1 (III)
MCI/CIND 4 83.5 (2.08) 0F/4 M 4.45 (2.30) 26.5 (3.11) 10.6 (5.8) 3 (II), 1 (III)
AD 6 79.8 (5.23) 4F/2 M 7.05 (4.05) 13.2 (9.87) 6.2 (4.8) 3 (V), 3 (VI)
Study 2
Non-DS young 6 22.3 (12.0) 3F/3 M 11.8 (5.6) N/A N/A N/A
Non-DS old 9 56.6 (12.2) 3F/6 M 7.4 (4.6) N/A N/A N/A
DS-young 5 19.0 (16.6) 1F/4 M 16.8 (9.7) N/A N/A N/A
DS-old 13 52.2 (8.20) 7F/6 M 7.3 (6.0) N/A N/A N/A
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123(TBS-A) and then blocked for 30 min in TBS-A with 3%
bovine serum albumin (TBS-B). Sections were incubated
overnight at room temperature in previously established
optimal primary antibody dilutions as indicated in
Table 2. Following two washes with TBS-A and a wash
in TBS-B, sections were incubated in either goat anti-
mouse or goat anti-rabbit biotinylated anti-IgG and then
in avidin biotin complex (ABC) (Vector Laboratories,
Burlingame, CA, USA). Antibodies were visualized using
horseradish peroxidase/3,30-diaminobenzidine (ABC Elite
kit, Vector Laboratories, Burlingame, CA, USA). For
quantiﬁcation experiments, the frontal cortex from all
cases used for quantiﬁcation was immunostained in single
experiments to reduce variability in the image analysis
procedures and all immunohistochemical procedures were
identical for the OC antibody. To determine the speciﬁcity
of the OC antibody, IgG puriﬁed from serum at a con-
centration of 1:10,000 was preincubated in 109 and
1009 concentration of ﬁbrillar Ab peptide for 2 h at RT.
Subsequently, a section from the midfrontal cortex was
incubated in the OC antibody/peptide solution and
processed for immunohistochemistry.
Immunoﬂuorescence and confocal microscopy
A series of double label immunoﬂuorescence experiments
were conducted to determine the colocalization character-
istics of OC with other markers of pathology. Primary
antibody dilutions are indicated in Table 2. Sections were
incubated in OC overnight and then detected using anti-
rabbit IgG Alexa Fluor 568 (Molecular Probes, Eugene,
OR 1:200). The appropriate second antibody was used to
serve as a marker for tau pathology (PHF-1), Ab (6E10),
oligomers (A11), dystrophic neurites (ubiquitin), activated
microglial cells (LN-3) and astrocytes (GFAP). In a subset
of DS cases, additional double label immunoﬂuorescence
was completed using Ab1-40 and Ab1-42 antibodies after
OC labeling. When possible, antibodies were selected that
were raised in different hosts. When not possible, for
double labeling experiments where both antibodies were
raised in the same species an intervening formaldehyde
treatment was used between the ﬁrst and second immu-
nolabel [72]. Alexa Fluoro 488 (Molecular Probes, Eugene,
OR 1:200) was used to visualize the second label (PHF-1,
ubiquitin, 6E10, LN-3, GFAP). Sections were allowed to
dry on slides prior to rehydration and coverslipping with
VectaShield (Vector Laboratories, Burlingame, CA, USA).
Confocal images were collected on a BioRad Radiance
2000 Confocal Imaging System with an Olympus IX70
inverted microscope using a 40, 60 or 1009 objective for
image analysis. Each antibody label was excited and
scanned separately using barrier ﬁlters at 510 and 480 nm.
Channel 1 was used to acquire immunoﬂuorescence with
Alexa Fluor 488 and channel 2 was used to collect ﬂuo-
rescent labeling with Alexa Fluor 568. A z-series scan at
either 0.5 or 1 lm intervals was captured to determine the
spatial colocalization characteristics of OC with other
markers of pathology. A subset of sections was ﬁrst
immunostained for OC and visualization with Alexa Fluor
568 and then counterstained with thioﬂavin S.
Quantiﬁcation
OC loads
Immunostaining by the OC antibody was captured from a
single section for each AD, DS and control case using a
209 objective, a Sony high-resolution CCD video camera
(XC-77) and the built-in video capture capabilities of a
Macintosh 8100/80AV. A random superﬁcial cortical
region containing OC immunostaining in samples that were
positive was selected and captured. For control cases, OC
immunostaining was scattered and thus the ﬁrst sample was
selected to include positive immunoreactivity if present, or
a random area if absent. This sampling approach is slightly
modiﬁed from that used by Cummings et al. [13], in that
Table 2 Antibodies used in the study
Antibody Used to detect Type Dilution Source
PHF-1 Neuroﬁbrillary tangles and dystrophic neurites Monoclonal 1:1,000 Dr. Peter Davies (Albert Einstein College
of Medicine, Bronx, NY, USA)
6E10 Senile plaques (Abeta 1-16) Monoclonal 1:5,000 Signet Laboratories, Inc., Dedham, MA,
USA
A11 Oligomers Polyclonal 1:100 Glabe-UCI
Anti-ubiquitin Dystrophic neurites Polyclonal 1:1,000 Novus Biologicals, Littleton, CO, USA
Anti-GFAP Astrocytes Polyclonal 1:2,500 Chemicon International, Temecula, CA,
USA
LN-3 Activated microglial cells Monoclonal 1:100 ICN Biomedicals, Irvine, CA, USA
Anti-Ab1-40 Ab1-40 Polyclonal 1:1,000 BioSource International
Anti-Ab1-42 Ab1-42 Polyclonal 1:2,000 BioSource International
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123we did not begin with a sample that appeared to have the
highest amount of OC immunoreactivity in AD cases.
From that initial sample area, four adjacent superﬁcial
ﬁelds were captured that were non-overlapping. Subse-
quently, the tissue was shifted to capture ﬁve deep cortical
ﬁelds that were non-overlapping but adjacent. Thus, a total
of 10 ﬁelds (including 5 superﬁcial and 5 ﬁelds containing
deep layers of cortex) were quantiﬁed from the midfrontal
gyrus for each human case. For the transgenic mouse study,
OC loads were obtained from the frontoparietal cortex, the
entorhinal cortex and from area CA1 in the hippocampus of
individual animals. To do this, two samples from each
cortical region was captured by starting above the cingulate
cortex and moving laterally for the frontoparietal measures
(ﬁelds captured included a superﬁcial and deep layer
sample), and from the most ventrolateral aspect of the
entorhinal cortex and moving dorsally. Fewer samples
were taken in mice as the cortical areas were smaller but to
maintain consistency with the human study, the same
magniﬁcation and capturing process was used. For area
CA1 in the hippocampus, a single ﬁeld was captured that
contained CA1 neurons as a row of cells through the center
of the ﬁeld. All samples from a given region were captured
sequentially during one session. Subsequently, public
domain image analysis software (NIH Image 1.55) and a
gray-scale threshold of 110 were used to separate positive
staining from background and to calculate the percentage
of area occupied by OC-positive labeling. The threshold
cutoff point was selected to be conservative and resulted in
a slight underestimation of the stained areas but minimized
the impact of non-speciﬁc background reactivity. With
this technique, individually captured ﬁelds measured
525 9 410 lm, which would allow us to quantify diffuse
plaques and neuritic plaques, however, deposits that
occupied less than 1% of any given area would not be
included due to the thresholding.
OC colocalization with neuritic and diffuse plaques
To obtain measures of co-localization between OC-positive
immunolabeling and neuritic plaques or diffuse plaques,
additional images were analyzed from confocal micros-
copy experiments. Confocal images captured from three
Down syndrome cases and with three controls were used to
obtain either neuritic plaque (thioﬂavin S-positive with
OC) or diffuse plaque colocalization (using OC and 6E10
labeled sections in cases that were thioﬂavin S-negative).
One image was captured (using a 209 objective such that 1
pixel = 0.18 lm) for each case for each double labeling
experiment. Image J (Rasband, W. S., ImageJ, U. S.
National Institutes of Health, Bethesda, MA, USA,
http://rsb.info.nih.gov/ij/, 1997–2008) and the JACoP plug
in [4] was used to obtain Manders’ overlap coefﬁcients,
which provides a proportion of the ‘‘green signal’’ coinci-
dent with the ‘‘red signal’’. Images were thresholded prior
to quantiﬁcation by ﬁrst determining a cut off for the
marker (OC or thioﬂavin or 6E10) that occupied the most
area in the image with the second marker automatically set
to the same threshold.
Statistical analysis
Linear regression analyses using the Huber–White robust
standard error estimator [74] were used to evaluate group
differences while co-varying for post mortem interval and
age at death.
Results
OC antibody characteristics
To determine if OC labeling was sensitive to formic acid
pretreatment, a procedure used to improve immunostain-
ing for ﬁbrils [39], serial sections from an AD case were
pretreated with 0, 10, 50, 70 and 90% formic acid for
4 min prior to incubation in OC antibody. After visuali-
zation with anti-rabbit conjugated to Alex Fluor 568,
sections were washed and then incubated in 6E10, which
shows an increase in immunolabeling with increasing
formic acid. Figure 1 shows confocal images from a
similar region in each serial section illustrating that
increasing formic acid concentration leads to increasingly
extensive 6E10 labeling but there is no change in OC
labeling. We next examined whether OC immunoreac-
tivity co-localizes with thioﬂavine-S, a marker for beta-
pleated sheet ﬁbrils but that there would also be distinct
deposits. Figure 2 shows that some OC-positive deposits
are also positive for thioﬂavin S suggesting an association
with mature plaques (63.4% of thioﬂavin S was positive
for OC). However, additional thioﬂavin-negative deposits
were detected by the OC antibody, particularly at the
periphery of mature plaques. It is possible that the OC
antibody can detect other types of amyloid such as, for
example, ﬁbrillar oligomers that are thioﬂavine S-negative
or alpha synuclein [35]. Further, OC-positive deposits had
a distinct morphology from thioﬂavine S-positive ﬁbrils
(Fig. 2a–c). Using tissue from a nondemented elderly
subject (Fig. 2d–f) and a younger individual with DS
(Fig. 2g–i), both having primarily diffuse plaques (thio-
ﬂavine S-negative), we observed that diffuse plaques are
also OC-positive (9.3% of OC-positive plaques were
thioﬂavin S-positive).
Additional experiments in DS and control cases were
used to measure the overlap in immunostaining between
OC and Ab40 or Ab42. When both OC and Ab40 were
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123present, we observed a range of colocalization from 17.6 to
62.5% of OC-positive deposits containing Ab40. However,
we observed individual plaques that were Ab40-positive
and OC-negative. Similarly for OC and Ab42, when both
were present, OC occupied 38.5% of Ab42-positive pla-
ques. However, we observed Ab42-positive plaques that
were also negative for OC. Thus, in this small set of
samples, we observed both Ab40 and Ab42-positive pla-
ques that were negative for OC but when both are present,
there was a higher association with OC to Ab40.
OC-positive deposits could also be distinguished from
A11-positive oligomers in mature plaques observed in DS
(Fig. 2j–m).
OC-positive deposits were characterized further to
determine if they were associated with dystrophic neurites
and glial cell responses (Fig. 3). OC-positive deposits
contain PHF-1 (Fig. 3a) and ubiquitin (Fig. 3c) positive
dystrophic neurites but a subset were negative (Fig. 3b).
Microglial activation (Fig. 3d, e) was associated with a
subset of OC-positive ﬁbrils and a subset of microglia
appear to have phagocytosed OC-positive material within
vacuoles (Fig. 3f). OC-positive deposits were also sur-
rounded by hypertrophic astrocytes (Fig. 3g, h).
OC immunostaining in AD and controls
To test the hypothesis that the extent of OC-positive ﬁbrils
was higher in AD cases relative to controls, and interme-
diate within those cases with select cognitive impairments
(cognitively impaired not demented—CIND or MCI), OC
labeled frontal cortex sections were quantiﬁed. Robust
linear regression was used to test for group differences,
adjusting for PMI and age at death. After adjusting for PMI
and age, there was a statistically signiﬁcantly higher OC
percentage load in AD patients compared to controls
(p value = 0.002, 95% CI for difference = 12.09, 37.56)
(Fig. 4a). Signiﬁcant differences in OC load were observed
as a function of Braak and Braak tangle staging primarily
due to higher levels in Braak stage V/VI (p = 0.002)(data
not shown). Figure 4b shows the results of a linear
regression that included the interval between last clinic
visit and death, that as dementia severity increases (low
Fig. 1 Formic acid
pretreatment has little effect
on OC labeling intensity.
Increasing concentrations of
formic acid pretreatment
(a none, b 10%, c 50%, d 70%,
e 90%) were used in an AD case
(frontal cortex) to illustrate no
change in OC (red ﬂuorescence)
immunolabeling but an increase
in 6E10 (green ﬂuorescence)
labeling. Note that with
increasing formic acid and
corresponding increase in 6E10
labeling, the extent of
co-localization of the two
markers also increases (orange
ﬂuorescence). In comparison,
a control case shows neither
signiﬁcant OC nor 6E10
immunolabeling (f). However,
a subset of OC-positive deposits
(g and i) was negative for
6E10 (h and i)
Acta Neuropathol (2009) 118:505–517 509
123MMSE score) there was a corresponding increase in OC
load (p = 0.0007).
OC in Down syndrome
We next asked the question whether OC immunoreactivity
accumulates as a function of age in DS cases, where typ-
ically, virtually all cases over the age of 40 years have
sufﬁcient pathology for a diagnosis of AD [50]. We ﬁrst
tested the hypothesis that PMI was not a signiﬁcant con-
tributor to OC load. However, we observed a signiﬁcant
association of PMI with OC load (p = 0.001) with longer
PMI’s associated with a loss of OC immunoreactivity and a
2.5% decrease in OC labeling with each 10-h block of PMI
(Fig. 4c). We further found a signiﬁcant interaction
between age and genotype group (DS vs. non-DS) with
aged DS individuals having higher overall levels of OC
labeling (p = 0.0004) (Fig. 4d).
OC in Tg2576 mice
Age-associated increases in OC labeling in individuals
with DS may be due to overexpression of the human APP
gene. To conﬁrm and extend this hypothesis, we used tis-
sue from Tg2576 mice, which overexpress mutant human
APP [31]. In a study of the brains of 30 Tg2576 animals,
we ﬁnd a signiﬁcant main effect of age on OC loads in the
frontoparietal cortex (F(5,29) = 5.90, p = 0.001), in the
entorhinal cortex (F(5,29) = 9.91, p\0.0005) and in area
CA1 of the hippocampus (F(5,29) = 9.94, p\0.0005).
Figure 5 shows that as with DS cases, there was a sudden
rise in the extent of OC labeling after the age of 12 months
Fig. 2 OC immunolabeling is
distinct from thioﬂavine
S-positive ﬁbrils within plaques
and also identiﬁes diffuse
plaque deposits. OC-positive
deposits (a) had a distinct
morphology that appears as
shorter aggregates (red)a s
compared to thioﬂavine
S-positive ﬁbrils (green)( b).
Further, when OC and
thioﬂavine-S was colocalized
within plaques (orange), OC
labeling was more intense in the
periphery (c). Using tissue from
a nondemented elderly subject
(d–f) and a younger individual
with DS (g–i), both having
primarily diffuse plaques
(thioﬂavine S-negative—green),
we observed that diffuse
plaques are also OC-positive
(red). A z-scan shows that
OC-positive deposits (green)
could also be distinguished from
A11-positive oligomers (red)i n
mature plaques observed
in DS frontal cortex
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123in Tg2576 animals. Initial deposits were observed at
6 months in one animal and in 4/5 animals at 9 months
of age. When 18- and 24-month old Tg2576 mice were
directly compared to wild type animals of the same ages,
the latter group had undetectable amounts of OC-positive
deposits (data not shown).
Discussion
Using a newly developed conformation-dependent, ﬁbril-
speciﬁc, polyclonal antibody [35] that recognizes a generic
epitope associated with ﬁbrils and soluble ﬁbrillar oligo-
mers we have characterized AD and age-associated
Fig. 3 Characteristics of
OC-positive deposits. A subset
of OC deposits (red) contained
dystrophic neurites labeled by
PHF (green arrows) that could
be distinguished from tangle
bearing neurons (arrowheads)
(a). Not all OC (red) deposits
contained PHF positive
dystrophic neurites (green)( b).
Dystrophic neurites labeled with
ubiquitin (green) were also
found in association with a
subset of OC deposits (red)( c).
A subset of OC (red) deposits
was associated with activated
microglial (LN-3 green)( d)
Area in d indicated by asterisk
at higher magniﬁcation
illustrating two activated
microglial cells (green)
surrounding an OC-positive
deposit (red)( e). A subset of
activated microglial cells
(green) appear to have engulfed
OC-positive material (arrows
red/orange) whereas other
microglial cells appear
OC-negative (arrowhead)( f).
OC-positive deposits (red) are
surrounded by astrocytes
(green)( g). A higher
magniﬁcation of the region in
g indicated by the asterisk
shows that some astrocytes in
proximity to OC appear
hypertrophied (h)
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123changes in Ab ﬁbril accumulation. Several technical
aspects to the use of the OC antibody were identiﬁed in the
current study. First, formic acid pretreatment, typically
used to enhance Ab immunostaining [39] does not signif-
icantly improve OC labeling. This suggests that the
epitope/conformation recognized by the OC antibody is not
obscured when ﬁbrils form and have not adopted a full
beta-pleated sheet assembly state. Second, based on our
studies in DS brain, post mortem interval may be a key
factor to consider when using this antibody. Longer post-
mortem intervals ([10 h) may be associated with a
degradation of the signal, possibly related to protease
activity. Whether this represents a loss of tissue morphol-
ogy, a spontaneous disassembly of ﬁbrils or oligomeric
protoﬁbrils or the opposite, a conversion into beta-pleated
sheet ﬁbrils post mortem, is difﬁcult to determine. Further,
a PMI effect on OC immunolabeling may potentially dis-
tinguish sporadic AD deposits from DS with AD deposits
and there is some evidence that the properties of Ab in
these two groups may behave differently [1].
OC-positive ﬁbrillar deposits accumulate in human
brain as overlapping deposits with thioﬂavine-S plaques
but are also found in deposits that are diffuse, i.e. thioﬂa-
vine S-negative. By examining the brains of individuals
with and without dementia, we show increased ﬁbrillar
accumulation in AD but when compared to controls.
However, CIND/MCI cases showed similar OC immu-
nolabeling as controls. Further, the extent of ﬁbril
accumulation in AD, CIND/MCI and control brain corre-
lates with the severity of cognitive decline measured by
MMSE scores. Similarly, in individuals with DS, we
observe ﬁbril accumulation that is both age- and AD neu-
ropathology-associated but with a rapid rise in levels after
the age of 40 years. Finally, in one of the most commonly
used animal models of Ab pathogenesis, we ﬁnd a rapid
age-dependent accumulation of ﬁbrils that is ﬁrst detect-
able at 6 months of age but dramatically increases after
12 months of age after overexpression of mutant human
APP in the Tg2576 model system. Thus, OC-positive
deposits may be visible histologically at an earlier age than
Fig. 4 The extent of OC labeling in AD and DS brain. More
extensive OC immunoreactivity was observed in the AD cases
relative to both the control and MCI/CIND cases (a). Higher MMSE
scores were associated with less extensive OC immunolabeling
(r =- 0.72, p\0.001) (b). In DS cases used in experiment 2, OC
labeling appears to be signiﬁcantly reduced when the PMI is over
10 h (c). A signiﬁcant increase in OC was observed in adults with DS
over the age of 40 years (open circles d) but not in similarly aged
non-DS controls (closed circles). When OC loads are plotted as a
function of individual age, there is an exponential rise in Ab ﬁbril
accumulation after the age of 40 years in DS (open circles) but not in
non-DS controls (closed circles)( d). Bars represent means and error
bars, standard errors of the mean. In b–d, the lines represent a best ﬁt
function
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123Ab-positive deposits reported previously [34] and may
represent an early neuropathological feature more consis-
tent with the onset of behavioral dysfunction [31].
OC-positive deposits that are thioﬂavine S-negative may
reﬂect ﬁbrillar oligomers. This is consistent with reports
that protoﬁbrillar forms of Ab have low thioﬂavine-T
response [75]. The morphology of the OC-positive, thio-
ﬂavine S-negative deposits are distinct and appear to be
shorter and wider than thioﬂavine S-positive ﬁbrils. In
addition, we frequently ﬁnd OC-positive deposits at the
periphery of thioﬂavine S-positive plaques providing fur-
ther evidence that soluble ﬁbrillar oligomers may represent
a reservoir for ﬁbril formation [35]. OC, interestingly, was
also able to detect diffuse plaques characterized as being
thioﬂavine S-negative but also containing intact neurons.
This may suggest that the pathogenesis of diffuse plaques
involves the accumulation of thioﬂavine S-negative ﬁbrils
and soluble ﬁbrillar oligomers. Interestingly, a similar
conclusion was made in an earlier study by Davies and
Mann [16] based on electron microscopy in biopsy samples
from AD cases showing diffuse plaques contained ﬁbrillar
material. Parallel studies in the canine model, that only
develop diffuse Ab plaques also suggests that these early
deposits are ﬁbrillar in nature [68]. Indeed, diffuse plaques,
though to be one of the earlier plaque subtypes accumu-
lating Ab pathology [27], contain primarily the longer toxic
Ab1-42 peptide [15, 26, 32], are observed at the threshold
of detectable dementia [56], can occur after traumatic brain
injury leaving affected patients at higher risk for develop-
ing AD [17] and may reﬂect synaptic activity induced Ab
Fig. 5 OC ﬁbril labeling in
Tg2576 animals. a Tg2576
animals show increasing OC
accumulation with age while no
OC was observed in comparably
aged wild type animals.
OC loads were obtained from
the b frontoparietal cortex,
c entorhinal cortex and d from
area CA1 in the hippocampus of
individual animals. Mean loads
are plotted as a function of age
for each brain region and show a
dramatic increase after
12 months of age in cortical
regions but with a slower more
progressive rise in the
hippocampus. Error bars
represent standard errors of the
mean (n = 5 animals/age
group)
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123production and release into the interstitial space [10].
Further, individuals with early onset AD caused by a
missense mutation in APP (T714I), develop primarily dif-
fuse Ab deposits and an aggressive form of dementia [40].
In combination, diffuse plaques may not be entirely benign
as has been suggested previously [51] although they may
be ‘‘clinically silent’’.
When OC is detected in more compact plaques, we
observe dystrophic neurites, microglial and astrocyte
involvement similar to previous reports of associated
neurodegeneration in these more mature plaque subtypes
[19]. Further, microglial cells may engulf OC-positive
deposits for degradation as we observe OC-positive mate-
rial within phagocytic vacuoles within HLA-DR expressing
microglial cells. We have observed a similar phenomenon
with oxidatively modiﬁed Ab [29] and others have reported
Ab within microglial cells in vitro and within AD brain
previously [21, 22, 60, 61, 65]. A critical role for mi-
croglial cells in clearing Ab from the brain has been
established in transgenic mice [3] and the results from this
study also suggest efforts by microglial cells to clear sol-
uble and insoluble ﬁbrils.
OC ﬁbrils in AD
We next used the OC antibody in studies to quantify the
extent of ﬁbril formation in individuals with and without
AD. OC-positive deposits were *7-fold higher in AD brain
relative to controls. However, based on previous studies in
the brains of individuals with MCI [57], we also predicted
that subjects with MCI or with a cognitive impairment
although not demented, may be either equivalent or inter-
mediate with respect to extent of OC-positive deposits.
However, we found that OC ﬁbrils were similar in MCI/
CIND as compared to nondemented aged controls. There
are two possible interpretations of these data. The ﬁrst is
that given our sample consisted primarily of CIND subjects;
there is a less clear relationship between CIND and pro-
gression to dementia as in MCI [62]. Second, ﬁbrils may be
more closely associated with full-blown dementia rather
than a possible pro-dromal selective clinical impairment.
By immunohistochemistry, we may also be detecting pri-
marily ﬁbrils as opposed to soluble oligomeric ﬁbrils, the
latter may be optimally detected using biochemical methods
[35]. Measures of soluble ﬁbrillar oligomers from protein
extracts of frozen tissue in these cases may be more sensi-
tive and reveal higher levels of OC in MCI/CIND cases
relative to controls because they have the potential of dis-
tinguishing insoluble ﬁbrils and soluble ﬁbrillar oligomers;
both of which react with OC. Another important consider-
ation is that the current study focused on plaque pathology
in the frontal cortex and had we sampled regions in other
vulnerable areas, particularly the entorhinal cortex (which
was not available for all cases), we may have observed OC
levels that are more consistent between MCI/CIND cases
and AD cases.
In AD brain, there are various reports of a correlation
between the extent of Ab deposition in plaques and the
severity of cognitive decline. For example, several studies
show a signiﬁcant inverse correlation with MMSE scores,
suggesting that lower scores associated with dementia are
linked to more extensive plaque formation [2, 13, 20, 58].
In contrast, additional studies do not show this relationship
and/or ﬁnd that neuroﬁbrillary tangles or synapse protein
loss, other key pathological features of AD, are also tightly
linked to cognition [12, 14, 23, 52, 58, 66]. Various
interpretations of these results have been suggested but one
hypothesis is that assembly state of Ab may be a critical
factor in determining its toxicity and thus the link to
impaired cognition. The current study suggests a signiﬁcant
correlation between OC-positive ﬁbrillar deposits and
MMSE scores with higher scores associated with intact
cognition linked to lower levels of OC. Interestingly, we
may be observing a threshold effect as OC loads increase
signiﬁcantly when MMSE scores drop below 20 but this
should be conﬁrmed in a larger cohort of cases.
OC ﬁbrils in Down syndrome
In the most common form of DS, trisomy 21, chromosome
21 is present in triplicate and leads to lifelong overex-
pression of the APP gene (21q21.2) [64]. Despite this life-
long overexpression of APP in brain and in peripheral
lymphocytes [59, 64], Ab accumulation in plaques does not
typically begin until after the age of 30 years [50],
although there have been reports of plaques in younger
individuals [43, 45]. Interestingly, the incidence of
dementia typically does not increase until adults with DS
are over the age of 50 years [41], suggesting the possibility
that either the brain can compensate for signiﬁcant Ab
accumulation or that Ab must adopt a speciﬁc conforma-
tion to become neurotoxic.
To test this hypothesis, we measured OC loads in indi-
viduals with DS with a range of ages. In the second
experiment, we observed an age-associated increase in OC
in DS that was not observed in similarly aged non-DS
subjects without dementia. In DS, it is possible to differ-
entiate initiation from acceleration phases of AD
pathogenesis. Between the ages of 30–40 years, the ﬁrst
signs of Ab plaques appear as diffuse deposits [47, 48].
Between 40 and 50 years, neuroﬁbrillary tangles also form
and neuritic plaques appear suggesting an acceleration
phase. We may also consider from 50 years and older as
when functional declines may occur [41]. If we classify
adults with DS into these groups, OC-positive ﬁbrils are
found as early as the initiation phase suggesting a key role
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123in Ab pathogenesis in DS. Despite life-long overexpression
of APP, the brains of individuals with DS under the age of
30 years were negative for ﬁbrils, however, a larger sample
of individuals between 20 and 30 years would extend these
ﬁndings. Thus, OC-positive deposits appear prior to the age
at which dementia prevalence rises in DS and may play a
role in AD pathogenesis in DS.
OC ﬁbrils in Tg2576
Similar to individuals with DS, transgenic mouse models
that overexpress mutant human APP develop Ab pathology
in a progressive age-dependent manner [31, 34]. In a sys-
tematic study of the different types and assembly states of
Ab that accumulate in Tg2576 mice, Kawarabayashi and
colleagues [34] showed that Ab in the form of plaques
appear as early as 7–8 months whereas diffuse plaques
appear between 12 and 15 months. However, Ab extracted
with formic acid can be detected using biochemical
approaches younger ages between 6 and 8 months. Further,
Ab oligomers are detected in older animals *12 months of
age as variably being increased [34] or decreased [44].
However, behavioral impairments may appear prior to
signiﬁcant Ab plaque pathology as early as 3 months [38],
6 months of age [73] or older [11, 31, 54]. The discrepancy
between the onset of behavioral dysfunction in Tg2576
mice and the age at which Ab plaques ﬁrst appear suggests
a critical role for different assembly states of Ab on neu-
ronal function. The earliest age at which we consistently
observed OC-positive deposits in the Tg2576 mice in the
current study was 9 months, with one animal at 6 months
of age showing pathology, but this does not rule out soluble
ﬁbrillar oligomers, which may not be detected by immu-
nohistochemistry, from being a contributor to neuronal
dysfunction. Indeed, Ab*56 oligomers that appear as early
as 7 months are A11-positive, indicating that they are
preﬁbrillar oligomers that would not be expected to react
with OC [44].
In summary, using a novel antibody that detects amyloid
ﬁbrils and soluble oligomeric protoﬁbrils we show a dif-
ferential distribution from beta-pleated sheet ﬁbrils and
association with AD in both the general population and in
adults with DS. Further, OC-positive ﬁbrils also accumu-
late in Tg2576 mice suggesting that several of the
dynamics involved with production and accumulation of
ﬁbrils may be modeled in this animal. It would be inter-
esting to selectively reduce OC-positive ﬁbrils through a
vaccination approach to determine their functional impact.
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